Could Cymabay Therapeutics, Inc. (CBAY) See a Reversal After This Very Strong Session?

February 20, 2018 - By Linda Rogers

The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) is a huge mover today! The stock increased 0.20% or $0.03 during the last trading session, reaching $15.01. About 678,817 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since February 20, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.
The move comes after 7 months positive chart setup for the $832.26 million company. It was reported on Feb, 20 by Barchart.com. We have $15.61 PT which if reached, will make NASDAQ:CBAY worth $33.29 million more.

Analysts await Cymabay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on March, 22. They expect $-0.13 EPS, up 56.67 % or $0.17 from last year’s $-0.3 per share. After $-0.21 actual EPS reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10 % EPS growth.

Cymabay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

Among 7 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc has $27.0 highest and $2.25 lowest target. $17.83’s average target is 18.79% above currents $15.01 stock price. Cymabay Therapeutics Inc had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The company was upgraded on Monday, January 30 by H.C. Wainwright. H.C. Wainwright initiated Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Tuesday, September 8 with “Buy” rating. The firm earned “Buy” rating on Wednesday, January 10 by Oppenheimer. Piper Jaffray maintained the stock with “Buy” rating in Tuesday, July 25 report. Piper Jaffray maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Wednesday, January 31. Piper Jaffray has “Buy” rating and $15.0 target. Roth Capital initiated the stock with “Buy” rating in Friday, July 1 report. Piper Jaffray initiated the shares of CBAY in report on Tuesday, July 21 with “Overweight” rating. The rating was maintained by H.C. Wainwright with “Buy” on Monday, July 17. Cantor Fitzgerald maintained the shares of CBAY in report on Wednesday, October 25 with “Buy” rating. The stock has “Neutral” rating by H.C. Wainwright on Wednesday, January 4.

Another recent and important Cymabay Therapeutics, Inc. (NASDAQ:CBAY) news was published by Streetinsider.com which published an article titled: “CymaBay Therapeutics (CBAY) Commences Common Stock Offering” on January 29, 2018.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $832.26 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: